NIMGenetics is a privately owned Spanish biomedical company, backed by the private equity Apposite, specializing in the design and commercialization of products and services for clinical genetic diagnosis. We develop exclusive genomic products and services essentially based on two technologies; microarrays and Next-generation sequencing. We have expanded the value of our high-performance genomic products and services to the international market, becoming a top leader in genomic analysis and human genetic diagnostics.
ENRIQUE SAMPER RODRÍGUEZ
CEO. Founding Partner of NIMGenetics.
JUAN CRUZ CIGUDOSA
CSO. Founding Partner of NIMGenetics.
SARA ÁLVAREZ DE ANDRÉS
CMO. Founding Partner of NIMGenetics.
JAVIER SUELA
CTO
ABELARDO BAÑOS
IT and Quality Manager
MIGUEL DEL CERRO
Director of Human Resources and Head of Corporate Communications
GUILLERMO CHIARRONI
Chief Business and Marketing Officer
FERNANDO ECHEVARRÍA
Chief Financial Officer
STUART MEDINA
International Business Development Director
For more information about our team, check on next link https://www.nimgenetics.com/en/team/
NIMGenetics is an innovative european company leader in the implementation of the genomics into clinical diagnosis.
We develop exclusive genomic products and services essentially based on two technologies; microarrays and Next-Generation Sequencing. We have expanded the value of our high-performance genomic products and services to the international market, becoming a top leader in genomic analysis and human genetic diagnostics.
NIMGenetics is a Spanish leading European company specializing in genetic diagnosis, using DNA microarrays, Next Generation Sequencing and FISH probes, all of them with medical applications in different areas (Gynecology, Paediatrics and Neuropaediatrics, Oncohematology, etc.) We consider our presence in foreign markets as a strategic cornerstone. This is the reason why we started our international expansion phase in the year 2016.
Our strategic goal is to provide medical specialists our diagnostic tools and our knowledge of the human genome in benefit of their patients.
In addition NIMGenetics is investing to reach markets that we understand can be the spearhead of our positioning and international development. By this way, we want that a greater number of physicians and patients can benefit from our diagnosis.
Nowadays, NIMGenetics is present in Brazil with a integral laboratory focused in patients and a team of geneticists highly qualified. Futhermore, we have collaborators in Mexico, Colombia, Chile, Peru, Paraguay, Uruguay, UK, Portugal and India.
NIMGenetics has development an investment plan for the next three years with this goals:
NIMGenetics makes genetics available to researchers and clinical specialists. Genomics reaches the vast majority of health areas, so our clients are in a wide range of specialties: pediatrics, neurology, immunology, oncology, cardiology, obstetrics, reproduction and other areas of medicine.
NIMGenetics se expande en Europa con la adquisición de Gene Predictis
NIMGenetics
NIMGenetics se convierte en la primera biotecnológica de diagnóstico genético humano del mundo en ser B Corp
NIMGenetics
Una madre, un árbol
NIMGenetics
Apposite Capital refuerza su apuesta por NIMGenetics
NIMGenetics
Apposite Capital apuesta por NIMGenetics
NIMGenetics
